
FDA approves Attruby to reduce cardio death in ATTR-CM patients
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), a near-complete (≥90%) stabiliser of Transthyretin (TTR). It is approved for the treatment of adults with Transthyretin amyloid cardiomyopathy (ATTR-CM) to reduce cardiovascular death and cardiovascular-related hospitalisation. The FDA approval is based on the ATTRibute-CM Phase III… Read More
